The global omics lab services market size is expected to reach USD 194.04 billion by 2030, registering CAGR of 13.72% during the forecast period, according to a new report by Grand View Research, Inc. The development of the market is attributed to growing integration of the genomics data into clinical workflow and rising adoption of direct-to-consumer omics. Moreover, rising demand for early disease diagnostic test, technological advancements aided with increasing government funding is further propelling growth of the overall market.
Growing recognition of omics' potential in human disease management and other nonconventional applications has fueled the implementation of omics data. This, in turn, has increased competition among firms to introduce products and technologies by leveraging available genetic information, capitalizing on the ample growth avenues in the market. Advanced laboratory analytics also support the development of precision and personalized medicine, which has an influence beyond general patient care. Thorough progress has already been made in the field of oncology, and developments in omics and single-cell micro technology have greatly benefited progress toward upcoming patient-centered approach.
Moreover, the field of oncology has benefited most from omics research, and one newly developed use of NGS clinical tests is for the quantification of circulating tumor DNA (ctDNA) from plasma. Numerous NGS technologies, such as Cancer Personalized Profiling by deep Sequencing, may be used. High-throughput RNA sequencing developments have brought light the importance of transcriptomics in biological and clinical research. RNA sequencing using NGS technologies or microarrays are two ways to perform transcriptomics. Proteomics and metabolomics are two domains that have been significantly characterized by improvements in NMR and MS technologies.
Furthermore, key players operating in the market are focusing on incorporating omics technology in early diagnosis. For instance, in May 2021, Burning Rock Biotech Limited launched PRESCIENT, first pan cancer, multi omics early detection study in China. In March 2022, PrognomiQ invested USD 46.0 million in advancing development of multiomics for early detection of cancer. In September 2022, Bertis launched Proteomic based research of its new biomarkers for diagnosis of ovarian cancer. Moreover, in July 2022, Mission Bio, Inc. launched Tapestri platform for single cell multiomics-based MRD detection in blood cancers. These initiatives and research in the field of omics for the development of early diagnosis tools is further propelling the overall omics labs services market growth.
Request a free sample copy or view report summary: Omics Lab Services Market Report
Epigenetic segment is expected to show fastest growth during the forecast period which can be attributed to the future potential offered by epigenetic analysis
Diagnostic labs segment held the largest market share in 2021 owing to the rising testing and availability of the wide range of resources for performing diagnostic tests
Hardware equipment segment dominated the omics lab services market in 2021 and is anticipated to show at fastest growth rate during the forecast period owing to Rapid technological advancements in genomics and transcriptomics through the development of hardware equipments
North America held the largest market share which can be attributed to the increasing adoption of genetic testing due to its high accuracy, sensitivity, and specificity
Grand View Research has segmented the global omics lab services market report based on the services, business, frequency of service, product, end-use and region:
Omics Lab Services Services Outlook (Revenue, USD Million, 2018 - 2030)
Genomics
Proteomics
Transcriptomic
Metabolomics
Epigenetics
Omics Lab Services Business Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Research Institutes
Diagnostic Labs
Omics Lab Services Frequency of Service Outlook (Revenue, USD Million, 2018 - 2030)
One-off
Repeat
Continuous
Omics Lab Services Product Outlook (Revenue, USD Million, 2018 - 2030)
Hardware Equipment (Instrument, Kits, Chips)
Testing / Lab (Services)
Analytics / Interpretation (Personalization and Interpretation)
Omics Lab Services End-Use Outlook (Revenue, USD Million, 2018 - 2030)
Cancer
Pharmaco
Prescription
Non-Prescription
Reproductive
Other Genetic Tests
Forensics
Population Studies
Skincare
Nutrition
Vitamins and Supplements
Genealogy
Other Categories
Omics Lab Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Rest of Europe
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Rest of MEA
List of key players in global Omics Lab Services Market
Agilent Technologies, Inc.
Beijing Genomics Institute (BGI)
Q2 Solutions
Spectrus
Flomics Biotech
PhenoSwitch Bioscience
QIAGEN
Quest Diagnostics Incorporated
Thermo Fisher Scientific, Inc.
Illumina, Inc.
"The quality of research they have done for us has been excellent..."